Abstract
Since the mid-1990s cyclin-dependent kinase (CDK) inhibition has been the subject of an intense drug discovery effort in the pharmaceutical industry and in some academic institutions. Although only few compounds have at present progressed into human clinical trials, the prospect of finding safe agents useful in therapy, particularly in the cancer setting, is still positive. Some trends can be observed that witness the impact of recent findings in CDK basic biological research and technology advancements on the evolution of the patent literature on CDK inhibition. A patent literature review of small organic molecules as CDK inhibitors comprising the years 2001 - 2004 is presented here, as many of the major pharmaceutical companies have shown a continued effort in the field.
| Original language | English |
|---|---|
| Pages (from-to) | 675-703 |
| Number of pages | 29 |
| Journal | Expert Opinion on Therapeutic Patents |
| Volume | 15 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - Jun 2005 |
Fingerprint
Keywords
- Cancer treatment
- Cell cycle
- Cyclin-dependent kinase (CDK)
- Inhibitor
ASJC Scopus subject areas
- Medicine (miscellaneous)
- Pharmacology
- Law
Cite this
Cyclin-dependent kinase inhibitors : A survey of the recent patent literature. / Pevarello, Paolo; Villa, Manuela.
In: Expert Opinion on Therapeutic Patents, Vol. 15, No. 6, 06.2005, p. 675-703.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Cyclin-dependent kinase inhibitors
T2 - A survey of the recent patent literature
AU - Pevarello, Paolo
AU - Villa, Manuela
PY - 2005/6
Y1 - 2005/6
N2 - Since the mid-1990s cyclin-dependent kinase (CDK) inhibition has been the subject of an intense drug discovery effort in the pharmaceutical industry and in some academic institutions. Although only few compounds have at present progressed into human clinical trials, the prospect of finding safe agents useful in therapy, particularly in the cancer setting, is still positive. Some trends can be observed that witness the impact of recent findings in CDK basic biological research and technology advancements on the evolution of the patent literature on CDK inhibition. A patent literature review of small organic molecules as CDK inhibitors comprising the years 2001 - 2004 is presented here, as many of the major pharmaceutical companies have shown a continued effort in the field.
AB - Since the mid-1990s cyclin-dependent kinase (CDK) inhibition has been the subject of an intense drug discovery effort in the pharmaceutical industry and in some academic institutions. Although only few compounds have at present progressed into human clinical trials, the prospect of finding safe agents useful in therapy, particularly in the cancer setting, is still positive. Some trends can be observed that witness the impact of recent findings in CDK basic biological research and technology advancements on the evolution of the patent literature on CDK inhibition. A patent literature review of small organic molecules as CDK inhibitors comprising the years 2001 - 2004 is presented here, as many of the major pharmaceutical companies have shown a continued effort in the field.
KW - Cancer treatment
KW - Cell cycle
KW - Cyclin-dependent kinase (CDK)
KW - Inhibitor
UR - http://www.scopus.com/inward/record.url?scp=21244450397&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=21244450397&partnerID=8YFLogxK
U2 - 10.1517/13543776.15.6.675
DO - 10.1517/13543776.15.6.675
M3 - Article
AN - SCOPUS:21244450397
VL - 15
SP - 675
EP - 703
JO - Expert Opinion on Therapeutic Patents
JF - Expert Opinion on Therapeutic Patents
SN - 1354-3776
IS - 6
ER -